Evidence map›Paper›PMID 36972204›Full record

ArticleJournal of the American Chemical Society2023

Tautomer-Specific Deacylation and Ω-Loop Flexibility Explain the Carbapenem-Hydrolyzing Broad-Spectrum Activity of the KPC-2 β-Lactamase.

Catherine L Tooke, Philip Hinchliffe, Michael Beer, Kirill Zinovjev, Charlotte K Colenso, Christopher J Schofield, Adrian J Mulholland, James Spencer

Open access · hybridAbstract read
In one paragraph

Article in Journal of the American Chemical Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Antibiotic resistance inFrontiers in microbiology · 2026
    Review
  10. Article
  11. Review
  12. Directed evolution of a beta-lactamase samples a wide variety of conformational states.Protein science : a publication of the Protein Society · 2025
    Article
  13. Article
  14. Article
  15. CombatingFrontiers in cellular and infection microbiology · 2025
    Review
  16. Article
  17. Molecular insights into the evolutionary trajectory of aAntimicrobial agents and chemotherapy · 2024
    Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Catherine L TookeSchool of Cellular and Molecular Medicine, Biomedical Sciences Building, University Walk, University of Bristol, Bristol BS8 1TD, United Kingdom.ORCID 0000-0003-2180-3235
Philip HinchliffeSchool of Cellular and Molecular Medicine, Biomedical Sciences Building, University Walk, University of Bristol, Bristol BS8 1TD, United Kingdom.ORCID 0000-0001-8611-4743
Michael BeerSchool of Cellular and Molecular Medicine, Biomedical Sciences Building, University Walk, University of Bristol, Bristol BS8 1TD, United Kingdom.ORCID 0000-0002-3879-3339
Kirill ZinovjevSchool of Biochemistry, Biomedical Sciences Building, University Walk, University of Bristol, Bristol BS8 1TD, United Kingdom.ORCID 0000-0003-1052-5698
Charlotte K ColensoSchool of Cellular and Molecular Medicine, Biomedical Sciences Building, University Walk, University of Bristol, Bristol BS8 1TD, United Kingdom.
Christopher J SchofieldChemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, Mansfield Road, University of Oxford, Oxford OX1 3TA United Kingdom.ORCID 0000-0002-0290-6565
Adrian J MulhollandCentre for Computational Chemistry, School of Chemistry, Cantock's Close, University of Bristol, Bristol BS8 1TS, United Kingdom.ORCID 0000-0003-1015-4567
James SpencerSchool of Cellular and Molecular Medicine, Biomedical Sciences Building, University Walk, University of Bristol, Bristol BS8 1TD, United Kingdom.ORCID 0000-0002-4602-0571
University of Bristol · GBUniversitat de València · ESUniversity of Oxford · GB

Funding

Biotechnology and Biological Sciences Research Council BB/J014400/1Biotechnology and Biological Sciences Research Council BB/L01386X/1Biotechnology and Biological Sciences Research Council BB/T008741/1Medical Research Council MC_PC_16092Medical Research Council MR/N002679/1Medical Research Council MR/P007503/1Medical Research Council MR/S014934/1Medical Research Council MR/T016035/1Wellcome Trust
6 · The paper itself

Abstract

KPC-2 (

Indexed as

Anti-Bacterial AgentsCarbapenemsBacterial Proteinsbeta-Lactamasesbeta-LactamsIsomerismKlebsiella pneumoniaeMeropenemAnti-Bacterial AgentsBacterial Proteinsbeta-lactamase KPC-2beta-Lactamasesbeta-LactamsCarbapenemsMeropenem

Identifiers

PMID36972204
PMCPMC10080687
OpenAlexW4361017438

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.